About Us  |  Our History

Building on 40 Years of Medical Device Excellence

In 1981, a group of physicists from Georgia Institute of Technology decided to develop and market radiological pharmaceuticals and devices to fight cancer. They founded Theragenics to advance that mission.

Over the years, Theragenics grew to become a global leader in radioactive brachytherapy seeds designed to treat prostate and other cancers. Its TheraSeed® and AgX100® implants have been used to treat hundreds of thousands of patients worldwide.

Our diversified portfolio now includes industry leading vascular surgery and interventional radiology devices, as well as products for interventional cardiology. Our capabilities have also broadened to include device design and development services. Our commitment to providing you with life-changing medical solutions remains the same.





Theragenics Timeline


Theragenics celebrates its 40th anniversary.


Theragenics acquires Arrotek™ Medical, a full-service medical device design consultancy, expanding operations into Sligo, Ireland.


Thergenics becomes a private company via acquisition by Juniper Investment Company. Theragenics continues to build on its foundation as a leading medical device company. 


Theragenics receives FDA 510(k) clearance for AgX100®, an Iodine-125 based brachytherapy seed.


Theragenics acquires NeedleTech Products, adding manufacturing capabilities in specialty needles.


Theragenics expands into interventional radiology and cardiology with the acquisition of Galt Medical, a manufacturer of vascular access devices.


Theragenics acquires CP Medical, a manufacturer of sutures and wound closure devices for veterinary and medical applications.


Theragenics diversifies its product line by purchasing an existing U.S. Iodine-125 prostate business. The purchase enabled Theragenics to supply both Palladium-103 and Iodine-125 based seeds.


TheraSeed® receives CE Marking, which allows Theragenics to market the device throughout Europe.


The first patient was treated with TheraSeed®.


TheraSeed®, a Palladium-103-based brachytherapy treatment, receives 510(k) clearance from the FDA.


Theragenics was originally founded as Nuclear Medicine, Inc. by a group of physicists at the Georgia Institute of Techology, with an initial focus to develop radiological devices to treat cancer.

271,000 +

Patients treated with our brachytherapy seeds

21M +

Brachytherapy seeds supplied to date

We Invest - 52,000 Sq ft

Footprint of the state-of-the-art Arrotek design facility

250+ Physicians

Rely on our brachytherapy seeds for their patients


About Us

We design and deliver innovative solutions that consistently improve patient outcomes.



Ready to join a dynamic team committed to advancing medical device innovation?

Contact Us

Get in touch to learn more about our products and services.